The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer.

[1]  Stacey A. Kenfield,et al.  Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. , 2015, European journal of cancer.

[2]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Jones,et al.  Testosterone treatment for men with chronic heart failure , 2004, Heart.

[4]  P. Warde,et al.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. D'Amico,et al.  Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. , 2012, International journal of radiation oncology, biology, physics.

[6]  K. Hemminki,et al.  What do prostate cancer patients die of? , 2011, The oncologist.

[7]  E. V. van Beek,et al.  Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. , 2006, European heart journal.

[8]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[9]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[10]  C. Hayward,et al.  Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. , 1999, Circulation.

[11]  K. Channer,et al.  The effect of testosterone on insulin sensitivity in men with heart failure , 2007, European journal of heart failure.

[12]  A. D'Amico,et al.  Death from high‐risk prostate cancer versus cardiovascular mortality with hormonal therapy , 2013, Cancer.

[13]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  U. Hoppe,et al.  Testosterone Induces Cytoprotection by Activating ATP-Sensitive K+ Channels in the Cardiac Mitochondrial Inner Membrane , 2004, Circulation.

[15]  Mats Lambe,et al.  Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Cavasin,et al.  Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. , 2006, American journal of physiology. Heart and circulatory physiology.

[18]  R. Kloner,et al.  Testosterone and the Cardiovascular System: A Comprehensive Review of the Basic Science Literature , 2013, Journal of the American Heart Association.

[19]  J. Gwathmey,et al.  Androgen receptors mediate hypertrophy in cardiac myocytes. , 1998, Circulation.

[20]  F. Dong,et al.  The Heart: A Novel Gonadotrophin‐Releasing Hormone Target , 2011, Journal of neuroendocrinology.

[21]  A. D'Amico,et al.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2010, Journal of the National Cancer Institute.

[23]  J. Mckinlay,et al.  Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. , 1998, Annals of epidemiology.

[24]  Ben He,et al.  Effects of Testosterone on Cytokines and Left Ventricular Remodeling Following Heart Failure , 2007, Cellular Physiology and Biochemistry.

[25]  T. Brown,et al.  Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. , 2003, American journal of physiology. Endocrinology and metabolism.

[26]  C. Angermann,et al.  Low circulating androgens and mortality risk in heart failure , 2009, Heart.

[27]  M. Kaushik,et al.  Cardiovascular disease and androgens: a review. , 2010, International journal of cardiology.

[28]  E. Schwarz,et al.  Myths and truths of growth hormone and testosterone therapy in heart failure , 2011, Expert review of cardiovascular therapy.

[29]  J. Denham,et al.  Androgen Deprivation Therapy for Prostate Cancer Does Not Increase Cardiovascular Mortality in the Long Term , 2012, Oncology.

[30]  Fred Saad,et al.  Intermittent androgen suppression for rising PSA level after radiotherapy. , 2012, The New England journal of medicine.

[31]  M. Nørgaard,et al.  Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. , 2014, European urology.

[32]  Yang Jiang,et al.  Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. , 2005, European journal of endocrinology.

[33]  Joseph L. Chin,et al.  Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy , 2013 .

[34]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[35]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[36]  H. Sandler,et al.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[38]  V. Montori,et al.  Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. , 2007, Mayo Clinic proceedings.

[39]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[40]  P. Ponikowski,et al.  Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival , 2006, Circulation.

[41]  P. Rossi,et al.  High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. , 2012, International journal of radiation oncology, biology, physics.

[42]  G. Grunwald,et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.

[43]  David Handelsman,et al.  Effects of testosterone and nandrolone on cardiac function: a randomized, placebo‐controlled study , 2007, Clinical endocrinology.

[44]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[45]  N. Keating,et al.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? , 2013, European urology.

[46]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[47]  F. Iellamo,et al.  Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. , 2009, Journal of the American College of Cardiology.

[48]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Curl,et al.  Testosterone modulates cardiomyocyte Ca(2+) handling and contractile function. , 2009, Physiological research.

[50]  P. Rossi,et al.  High-dose radiotherapy with or without androgen-deprivation therapy for intermediate-risk prostate cancer: Cancer control and toxicity. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[52]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[53]  H. Sandler,et al.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. , 2008, European urology.

[54]  M. Wirth,et al.  Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.

[55]  M. Schonlau,et al.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer , 2007, Cancer.

[56]  S. Johansson,et al.  Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer , 2011, Drug safety.

[57]  A. Zietman,et al.  Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer , 2008, Cancer.

[58]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[59]  S. Shaw,et al.  Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. , 2009, Cardiovascular therapeutics.

[60]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[61]  M. Cooperberg,et al.  Androgen deprivation therapy and cardiovascular risk. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Tomoda,et al.  Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. , 1999, The American journal of cardiology.

[63]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[64]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[65]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[66]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.